Difference between revisions of "Team:Austin UTexas/Description"

Line 123: Line 123:
 
<div id="section2" class = "naviSection">
 
<div id="section2" class = "naviSection">
 
<h2> Conjugation  </h2>
 
<h2> Conjugation  </h2>
<p> In order to demonstrate that we can genetically engineer the bacterial strains that we identified, <i>Gluconobacter oxydans</i> and <i>Gluconacetobacter xylinus</i>, we attempted to conjugate various plasmids encoding fluorescent devices, such as GFP and E2 Crimson, into these bacteria using a DAP (Diaminopimelic Acid) auxotroph strain of <i>E. coli</i>.<sup>1</sup> To assist in this process, we also conducted minimal inhibitory concentration studies with each of these bacteria using spectinomycin, kanamycin and carbenicillin.  Ultimately, we determined that <i>G. oxydans</i> is able to survive the standard <i> E. coli </i> antibiotic concentrations we have been using for both spectinomycin and carbenicillin. However, <i>G. oxydans</i> was successfully inhibited by the normal amount of kanamycin. With this data, we can improve our conjugations by either using more concentrated amounts of spectinomyin and carbenicillin, or only using donor strains with kanamycin resistance. The plasmids pBTK518, pBTK519 and pBTK520 contain GFP and either a carbenicillin, kanamycin or a spectinomycin resistance gene respectively. Once the bacteria are successfully conjugated, we can introduce other constructs into <i>G. oxydans</i> in order to create a designer beverage.
+
<p> In order to demonstrate that we can genetically engineer the bacterial strains that we identified, <i>Gluconobacter oxydans</i> and <i>Gluconacetobacter xylinus</i>, we attempted to conjugate various plasmids encoding fluorescent devices, such as GFP and E2 Crimson, into these bacteria using a DAP (Diaminopimelic Acid) auxotroph strain of <i>E. coli</i>.<sup>1</sup> To assist in this process, we also conducted minimal inhibitory concentration studies with each of these bacteria using spectinomycin, kanamycin and carbenicillin.  Ultimately, we determined that <i>G. oxydans</i> is able to survive the standard <i> E. coli </i> antibiotic concentrations we have been using for both spectinomycin and carbenicillin. However, <i>G. oxydans</i> was successfully inhibited by the normal amount of kanamycin. With this data, we can improve our conjugations by either using more concentrated amounts of spectinomyin and carbenicillin, or only using donor strains with kanamycin resistance. The plasmids pBTK518, pBTK519 and pBTK520 (given to us by Jiri Perutka of The Ellington Lab) contain GFP and either a carbenicillin, kanamycin or a spectinomycin resistance gene respectively. Once the bacteria are successfully conjugated, we can introduce other constructs into <i>G. oxydans</i> in order to create a designer beverage.
 
<h3>References</h3>
 
<h3>References</h3>
 
<ol type="1">
 
<ol type="1">

Revision as of 05:07, 19 October 2016

Project Description


Gold Medal Part Characterization

The characterization of the BioBrick P-atp2 from the BIT-China-2015 team was done to see if P-atp2 could be utilized as a basic pH sensor. The results are found here and on the iGEM Registry page under experience, BBa_K1675021


Our Project

Kombucha is a beverage made when a symbiotic community of bacteria and yeast ferments sugared tea. Although kombucha has been consumed for thousands of years in the East, the drink has enjoyed a recent surge in popularity.1 Several kombucha breweries operate in Austin, Texas, our team’s hometown. The role microbes play in the production of the beverage has led our team to wonder if synthetic biology could allow us to create “designer kombucha” with enhanced properties, such as more appealing flavors or additional nutrients. In order to do so, our team attempted to isolate the strains responsible for the fermentation of kombucha, identify them, genetically modify them, and add the individual strains into tea media to recreate the drink. We additionally considered potential applications of the ability to genetically modify the microbial population of kombucha, such as reducing the ethanol content of the beverage and improving taste with brazzein, a sweet-tasting protein. In consideration of Human Practices, we reached out the Austin kombucha community to learn more about what kombucha brewers and consumers would want in a customizable kombucha. Through this interaction, we learned that many kombucha consumers and manufacturers value the traditional, all-natural process of producing the beverage, and that many in the industry would be apprehensive of kombucha made with genetically modified organisms. Though we hope increased public awareness of synthetic biology may someday make a genetically modified kombucha marketable, the current attitudes of kombucha consumers have led us to consider methods of creating designer kombucha that rely only on natural genetic variation.

References

  1. Kombucha Brewers International

Click the images below to learn more about our project!

Kombucha Strains

Conjugation

Recapitulation

Ethanol

Brazzein

pH Sensors